Pulmatrix, Inc. (PULM): Submission of Matters to a Vote of Security Holders

Pulmatrix, Inc. (PULM) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders In connection with the Merger, Pulmatrix held a special meeting in lieu of the annual meeting of Pulmatrix stockholders on October 26, 2026, at 8:30 a.m. Eastern Time (the “Special Meeting”), at which the Pulmatrix sto

Event · Shareholder vote
Original reporting
Published Oct 27, 2026, 1:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 1:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$PULM
Neutral
high confidence
Mentioned
$PULM
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PULMNeutralMed
01

Why it matters

The approvals set the stage for a reverse stock split and increased authorized shares, which may dilute existing shareholders and affect short‑term price dynamics.

02

Market read

Primary corporate action disclosure with modest trading relevance; informs investors of upcoming share structure changes.

03

What to watch

Potential regulatory approvals and timing of the merger could mitigate dilution concerns.

Relevance 6/10Novelty 6/10Timing: today

Background

Pulmatrix filed a Form 8‑K reporting the results of a special shareholder meeting held to approve several proposals tied to its pending merger with Eos.

Company-level read

Ticker impact

$PULMNeutralHigh confidence
Context

SEC 8‑K disclosed shareholder approval of a reverse stock split, charter amendment to increase authorized shares, and issuance of new shares related to the pending merger.

Expected impact

likely downward pressure as investors price in dilution and uncertainty around the reverse split.

Evidence & confidence

The filing confirms material corporate actions that can affect share count and control, which typically weigh on the stock until the merger completes.

Market effects

Minimal impact on the broader biotech sector; the news is specific to Pulmatrix.

Limited to U.S. markets where Pulmatrix trades.

Low; no global market shift expected.

Counterpoint

If the merger proceeds smoothly, the reverse split could improve liquidity and support a price rally.

Key entities

  • Pulmatrix, Inc.

    Biotech company undergoing a merger with Eos.

  • Eos SENOLYTIX, Inc.

    Merger partner of Pulmatrix.

Related articles

$PULMMed

Pulmatrix Announces Third Quarter 2026 Financial Results and Progress on Merger

Pulmatrix, Inc. (PULM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pulmatrix Announces Third Quarter 2026 Financial Results and Progress on Merger Merger with Eos SENOLYTIX expected to close by end of the year Framingham, Mass., November 17, 2026 – Pulmatrix, Inc. (“Pulmatrix”, the “Company” or “our”) (Nasdaq: PULM), a biopharmaceut

$PULMMedAI 8/10

Eos reports early rat study data for aging drug candidate

Eos SENOLYTIX reported interim data from a rat study of its aging drug candidate PTC-2105, showing improved motor performance and reduced fat mass. The 32-week study involves 268 rats, with the oldest cohort showing positive results. Eos plans FDA submission and human trials in 2027. The company is merging with Pulmatrix Inc. (PULM), expected to close in Q4 2026.

$PULMMed

Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger

Pulmatrix, Inc. (PULM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger Form S-4 filed related to the announced merger agreement with Eos SENOLYTIX Framingham, Mass., August 13, 2026 – Pulmatrix, Inc. (“Pulmatrix” or the “Company”) (Nasdaq: PULM), a biopharm